NCPA's qAM

qAM

Dietary supplement linked to fetal harm

by NCPA | Jun 04, 2019

Pharmacists should read the FDA's statement warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine and be prepared to help patients identify the ingredient in products on the shelf or already at home. Vinpocetine may be referred to on product labels as Vinca minor extract, lesser periwinkle extract, or common periwinkle extract. Dietary supplements containing vinpocetine are often marketed for uses that include enhanced memory, focus, or mental acuity; increased energy; and weight loss. Animal studies concluded that vinpocetine decreased fetal weight and increased the chances of a miscarriage.